http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
-
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
-
Bausch Health (BHC) Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod to Treat UC
-
DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
-
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
-
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, Accor
-
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
-
Bausch Health Announces Third-Quarter 2023 Results
-
Bausch Health Announces Third-Quarter 2023 Results
-
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
-
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
-
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
-
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk
-
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
-
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
-
Salix Pharmaceuticals Partners with Bellamy Young
-
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action – BHC
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHC
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHC
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BHC
-
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
-
Bausch Health (BHC) Enters $600M Financing Facility With KKR (KKR)
-
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
-
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
-
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
-
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
-
Bausch Health Observes Mental Health Awareness Month
-
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
-
Bausch Health Announces First-Quarter 2023 Results
-
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
-
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
-
Bausch Health to Announce First-Quarter 2023 Results on May 4
-
New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
-
Bausch Health Co. Inc. (BHC) Announces Board Changes
-
Bausch Health Announces Changes to its Board of Directors
-
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
-
Carl Icahn trims Cheniere Energy (LNG) in Q4 - 13F
-
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
-
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
-
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents
-
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
-
Bausch Health Announces Third-Quarter 2022 Results
-
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
-
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
-
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
-
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
-
SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION
-
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
-
SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY

